China Pharma Holdings, Inc. Receives SFDA Production Approval for Tiopronin Enteric-Coated...

China Pharma Holdings, Inc. Receives SFDA Production Approval for Tiopronin
Enteric-Coated Capsules

HAIKOU CITY, Hainan, China, Jan. 12 /PRNewswire-Asia-FirstCall/ -- China
Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which
develops, manufactures, and markets specialty pharmaceutical products in
China,
today announced that China's State Food and Drug Administration ("SFDA")
approved the production of Tiopronin Enteric-Coated Capsules. Tiopronin is
listed in the National Medical Insurance Program, thus allowing patients to
obtain reimbursement.
Tiopronin Tablets are widely prescribed in several countries for the
treatment of acute and chronic Hepatitis B (HB), and for the relief of
drug-induced liver injury. However, this drug can cause stomach irritation
therefore its use and patient compliance may be limited by the side effects.
To address this, China Pharma has developed Tiopronin Capsules with an enteric
coating to decrease the stomach mucosal irritation associated with Tiopronin.
As a result, China Pharma's Tiopronin Enteric-Coated format improves liver
function while protecting the stomach.
Ms. Zhilin Li, China Pharma's president and CEO stated: "The competitive
advantage of our enteric coating, coupled with the reimbursement available,
make Tiopronin Enteric-coated Capsules a superior treatment option for liver
disease. According to Chinese epidemiological surveys, there are
approximately 30 million chronic HB patients in China, and around 120 million
carriers of the HB virus, which is 9.95% of the entire population. Therefore,
liver disease is a major threat for the Chinese population. Sales of liver
protection drugs including Tiopronin, have been projected to reach RMB 41.3
billion in 2008*. The increased intestinal absorption of our product,
Tiopronin Enteric-Coated Capsules, is consistent with reduced gastric
irritation, and higher bioavailability. All these advantages of the
enteric-coated format which is the fruit of our product differentiation
strategy, will create a stronger market position for China Pharma and bring
positive influence on our 2009 operating targets."
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company with
rapidly growing profit that develops, manufactures, and markets treatments for
a wide range of high incidence and high mortality conditions in China,
including cardiovascular, CNS, infectious, and digestive diseases. The
Company's cost-effective, high margin business model is driven by market
demand and supported by a scalable GMP-certified manufacturing infrastructure.
In addition, the Company has a broad and expanding distribution network across
30 provinces, municipalities and autonomous regions. The Company is
registered in Delaware, USA. Hainan Helpson Bio-pharmaceutical Co., Ltd
(Helpson), located in Haikou City, Hainan Province, China, is a wholly owned
subsidiary of China Pharma Holdings, Inc. For more information about China
Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
Safe Harbor Statement: Certain statements in this press release and oral
statements made by China Pharma on its conference call in relation to this
release, constitute forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995. Any
statements set forth above that are not historical facts are forward-looking
statements that involve risks and uncertainties that could cause actual
results to differ materially from those in the forward-looking statements,
which may include, but are not limited to, such factors as unanticipated
changes in product demand, increased competition, failure to obtain or
maintain intellectual property protection, downturns in the Chinese economy,
uncompetitive levels of research and development, failure to obtain regulatory
approvals, and other information detailed from time to time in the Company's
filings and future filings with the United States Securities and Exchange
Commission. The forward-looking statements made herein speak only as of the
date of this press release and the Company undertakes no duty to update any
forward-looking statement to conform the statement to actual results or
changes in the company's expectations.
* Source: MEDICINE ECONOMIC NEWS Jun. 24, 2005

For more information, please contact:

China Pharma Holdings, Inc.
Diana Huang
Tel: +86-898-6681-1730
Email: hps@chinapharmaholdings.com

The Ruth Group
Sara Ephraim
Tel: +1-646-536-7002
Email: sephraim@theruthgroup.com

SOURCE China Pharma Holdings, Inc.

Diana Huang of China Pharma Holdings, Inc., +86-898-6681-1730, or
hps@chinapharmaholdings.com; Or Sara Ephraim of The Ruth Group, +1-646-536-
7002, or sephraim@theruthgroup.com